Market Cap
$7.9M
SNGX
SOLIGENIX, INC.
$0.3653 ▲ +1.47%
Prev close $0.3600Market cap$7.9M
12-mo target$1.38 (+276.4%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on SNGX right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
12 funds
Inst. Value
$284.5K
Inst. Activity
2 buys / 1 sells
Social Sentiment
63° Warm
SEC Reports
5
Price chart 30d -3.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 17, 2026 Insider
ZELDIS JEROME B was granted 78,947 shares
Director
Sep 17, 2026 Insider
Parks Diane L. was granted 78,947 shares
Director
Sep 17, 2026 Insider
RUBIN ROBERT J. was granted 78,947 shares
Director
Aug 12, 2026 earnings_calendar
Jul 3, 2026 SEC SNGX Q2 2026 Earnings Scheduled — 2026-08-12
Soligenix filed a prospectus supplement to increase its at-the-market (ATM) equity offering capacity by $2.5 million, br
8-K — Impact 6/10
Jun 30, 2026 Inst.
OSAIC HOLDINGS, INC. — TRIM
1 shares (—)
Jun 30, 2026 Inst.
Jun 26, 2026 SEC VANGUARD CAPITAL MANAGEMENT LLC — ADD
81,005 shares ($32.1K)
Soligenix, Inc. filed a 424B5 prospectus supplement to increase the maximum dollar amount of common stock it can sell un
424B5 — Impact 7/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 16, 2025 | Alliance Global Partners | MAINTAIN | Buy | 42% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Price targets
Where 2 covering analysts think SNGX trades over the next 12 months.
$1.38 +276.4% upside Strong Buy
Current$0.3653 Low$1.25 Median$1.38 High$1.50 2 analysts
$1.25$1.50
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
63°
Warm
BearishNeutralBullish
Recent posts
🚨 Ebola Virus Alert 🌍 As global health concerns rise again, biotech and diagnostic companies could see major attention from investors. 📈 Keeping an eye on:✅ CODX✅ SNGX
▲ 1 · 💬 0· ⚡ 0.5
🚨 Ebola Virus Alert 🌍 As global health concerns rise again, biotech and diagnostic companies could see major attention from investors. 📈 Keeping an eye on:✅ CODX✅ SNGX
▲ 1 · 💬 1· ⚡ 0.5
SNGX: With the imminent Phase 3 interim data coming soon, this is due for an aggressive re-rate
▲ 1 · 💬 0· ⚡ 0.5
Interesting analysis on SNGX
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 5 bearish, 0 mixed, 0 neutral · avg impact 6.0/10.
BEARISH8-K6/10
Soligenix filed a prospectus supplement to increase its at-the-market (ATM) equity offering capacity
Jul 3, 2026
BEARISH424B57/10
Soligenix, Inc. filed a 424B5 prospectus supplement to increase the maximum dollar amount of common
Jun 26, 2026
BEARISH8-K5/10
Soligenix filed an 8-K to increase the maximum aggregate offering amount under its existing at-the-m
May 28, 2026
BEARISH424B56/10
Soligenix filed a 424B5 prospectus supplement to update the maximum dollar amount of common stock it
May 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
Clinical Trial
Dusquetide for the Treatment of Behcet's Disease
Phase Phase 2 — COMPLETED
Aug 25, 2026
Clinical Trial
Topical SGX302 for Mild-to-Moderate Psoriasis
Phase Phase 2 — COMPLETED
Aug 12, 2026
earnings_calendar
SNGX Q2 2026 Earnings Scheduled — 2026-08-12
Aug 11, 2026
Clinical Trial
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Phase Phase 3 — TERMINATED
Aug 7, 2026
earnings
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on develo
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.09 | $-0.09–$-0.09 | 84.5% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $-0.07 | $-0.07–$-0.07 | — | +0.0% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-0.40 | $-0.40–$-0.40 | 81.3% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-0.25 | $-0.25–$-0.25 | 37.5% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.090 | — |
| 7d ago | $-0.090 | — |
| 30d ago | $-0.090 | — |
| 60d ago | $-0.090 | — |
| 90d ago | $-0.090 | — |
Institutional ownership
Which big funds own SNGX (from quarterly 13F filings) and who is adding or trimming.
12 institutional holders with $284.5K total value (718,311 shares) as of 2026-Q2. Top holders: ROYAL, OSAIC, CITADEL. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 5 | $0.00 | 0.0% | — |
| OSAIC HOLDINGS, INC. | 1 | $0.00 | 0.0% | TRIM -50.0% |
| CITADEL ADVISORS LLC | 209,507 | $83.0K | 29.2% | — |
| JANE STREET GROUP, LLC | 207,492 | $82.2K | 28.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 120,267 | $47.6K | 16.7% | ADD +49.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 81,005 | $32.1K | 11.3% | ADD +38.7% |
| VANGUARD FIDUCIARY TRUST CO | 53,914 | $21.4K | 7.5% | — |
| NORTHERN TRUST CORP | 38,046 | $15.1K | 5.3% | — |
| MORGAN STANLEY | 3,592 | $1.4K | 0.5% | DOUBLED +1603.6% |
| MERCER GLOBAL ADVISORS INC /ADV | 3,001 | $1.2K | 0.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| OSAIC HOLDINGS, INC. | TRIM | 2 | 1 | -50.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 58,400 | 81,005 | +38.7% | $32.1K |
| JONES FINANCIAL COMPANIES LLLP | DOUBLED | 100 | 1,236 | +1136.0% | $507.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 80,401 | 120,267 | +49.6% | $141.9K |
| UBS Group AG | NEAR_EXIT | 34,014 | 2,346 | -93.1% | $2.8K |
| OSAIC HOLDINGS, INC. | DOUBLED | 1 | 2 | +100.0% | $2.00 |
| VANGUARD GROUP INC | ADD | 52,522 | 85,468 | +62.7% | $114.5K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 42,590 | 80,401 | +88.8% | $107.7K |
| UBS Group AG | DOUBLED | 183 | 34,014 | +18486.9% | $45.6K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 35 | 88 | +151.4% | $118.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 4 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | ZELDIS JEROME B | Director | AWARD | 78,947 | — | — |
| Sep 17, 2026 | Parks Diane L. | Director | AWARD | 78,947 | — | — |
| Sep 17, 2026 | RUBIN ROBERT J. | Director | AWARD | 78,947 | — | — |
| Sep 17, 2026 | LAPOINTE ANTHONY GREGG | Director | AWARD | 78,947 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SNGX.
Shares short
202,558
Settlement Sep 15, 2026
Change vs prior
-3.8%
Semi-monthly cycle
Days to cover
1.6
At avg daily volume
Of shares outstanding
≈0.9%
Estimate — not % of float
All SNGX filing & press-release reports (5)
- 8-K reportJul 3, 2026
- 424B5 reportJun 26, 2026
- 8-K reportMay 28, 2026
- 424B5 reportMay 28, 2026
- EFFECT reportApr 3, 2026